Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss on the scalp, face, and body, affecting approximately 2% of the global population. Current treatments, including topical corticosteroids, topical immunotherapies, and systemic immunosuppressants, often demonstrate inconsistent efficacy and raise concerns about long-term safety, emphasizing the need for safer and more effective therapies. Janus kinase (JAK) inhibitors have emerged as a promising treatment option, offering a targeted approach by addressing the immune-mediated mechanisms driving hair follicle destruction in AA. Recent clinical advances have led to FDA approval of three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—based on pivotal trials showing significant hair regrowth. Baricitinib has demonstrated durable efficacy, with 35–40% of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 at 36 weeks. Ritlecitinib similarly reported 23% of patients achieving a SALT score ≤ 20 at week 24.
Are Tart or Sweet Cherries Better for Your Health? A Dietitian Breaks Down Their Benefits
This green apple-flavored gummy is formulated with minoxidil and biotin to help with hair regrowth. Delgocitinib is a selective JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) inhibitor that blocks multiple cytokine-mediated fda approves first drug to treat hair loss caused by alopecia signaling pathways (Table 1) 68. Delgocitinib has a half-life of ~ 20 h with topical administration, and peak plasma levels occur within 2–6 h following topical application 69. Topical bioavailability is roughly 0.6% compared to systemic administration 69. As mentioned above, tofacitinib selectively inhibits JAK1 and JAK3, blocking downstream cytokine signaling 62. Topical tofacitinib penetrates the stratum corneum and reaches the deep layers of epidermal and dermal layers.
Understanding hair loss treatments has never been so easy.
This makes it an effective option for extensive or severe cases of alopecia areata approved by the FDA. This article explains how these treatments work and what makes them effective. People suffering from a rare autoimmune disorder that causes their hair to suddenly fall out, often in clumps, now have a treatment option for the first time.
FDA-Approved Hair Loss Treatments for Androgenic Alopecia
Ivarmacitinib, a JAK3 selective inhibitor, has recently undergone a phase 2 clinical trial in which it has demonstrated efficacy in AA 73. Jaktinib, a novel JAK1 and JAK2 inhibitor, has been evaluated in severe AA via an open-label phase 2 study; the results have still not been made publicly available 74. Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, is FDA approved for treatment of plaque psoriasis but has also shown promise in AA.
It is currently in phase 2 clinical trials to evaluate safety and efficacy, and a case report has shown improvement in AU by SALT score 75. Baricitinib was the first JAK inhibitor approved in June 2022 after pivotal trials demonstrated its efficacy in adults with severe AA 13. This approval was followed by ritlecitinib in June 2023 for patients aged ≥ 12 years 13.
- People suffering from a rare autoimmune disorder that causes their hair to suddenly fall out, often in clumps, now have a treatment option for the first time.
- NBC News medical contributor Dr. Natalie Azar says the breakthrough drug won’t be widely available to all alopecia patients.
- These top-rated supplements combine saw palmetto with vitamins B6, B9, and D and adaptogenic mushrooms like maitake and reishi.
- Losing between 50 to 100 hairs per day is normal, but shedding beyond that can be concerning and stressful.
- It is the third FDA-approved medication to treat alopecia areata, which affects an estimated 700,000 Americans.
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
«Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,» said FDA official Kendall Marcus in a statement. «Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.» «Today’s approval will help fulfill a significant unmet need for patients with severe alopecia areata.»
Antioxidant effects of ADSCs
(Keep in mind that hair regrowth isn’t always possible.) “I’ve seen people go from hair loss of about one quarter in size to alopecia totalis” without proper treatment by a medical professional, says Dr. Williams. “Access to safe and effective treatment options is crucial for the significant number of Americans affected by severe alopecia,” said FDA official Kendall Marcus in a statement. Its approval for use against alopecia was based on the results of two randomized, controlled clinical trials involving a total 1,200 adults with severe alopecia. Olumiant (baricitinib) is an oral tablet to treat adult patients with severe alopecia areata, the FDA said. This can have a massive effect on a person’s quality of life, especially when it causes them to feel self-conscious and embarrassed about their appearance. Adolescents, in particular, are often excluded, teased, and bullied by their peers due to their hair loss.
- In Pfizer’s study, 718 people took the drug, administered via a pill, once a day at a 10-, 30-, or 50-milligram dose for 24 weeks, after previously taking either a 200-mg daily dose or a placebo pill for 24 weeks.
- Additionally, the review discusses various pre-treatment methods designed to enhance the regenerative capacity of ADSCs in hair growth, elucidating the mechanisms involved.
- Newer approaches like microneedling and LED therapy, she adds, may cause mild irritation or discomfort at the treatment site.
- A large network meta-analysis of JAK inhibitors in AA challenges these findings because of the limited sample size, delineating the ongoing uncertainty regarding the agent’s efficacy 67.
- Nearly 20% or about 1 in 5 people with alopecia areata are diagnosed with the condition before the age of 18.
“It essentially sends these signals that put the hair growth stem cells to sleep and they don’t wake up,” says Dr. Oro. The follicles are there, ready to grow, but the immune system goes haywire and prevents those follicles from doing their job. “Ritlecitinib is a JAK3 inhibitor and was just recently approved to be safe for adolescence after a series of clinical studies including the last study, which included 718 participants with 50% or more full scalp hair loss,” said Gaunitz. In the recent clinical trial on LITFULO, more than 700 patients with alopecia were enrolled from 18 nations. Every participant had experienced hair loss on half their scalp for less than a decade, and half the cohort had experienced total scalp hair loss.
Neovascularized effects of ADSCs
Measurable systemic levels of tofacitinib were detected using 2% ointment, suggesting systemic absorption does occur, albeit to a negligible degree compared to oral formulations 63. Currently, data on the pharmacokinetics of topical tofacitinib are significantly limited compared to its oral formulation. Many popular and brand-name serums seek to address hair loss or thinning hair on other parts of the body.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. For more than 170 years, we have worked to make a difference for all who rely on us.
The National Alopecia Areata Foundation says the condition affects about 2% of the population, or as many as almost 7 million Americans, with more than 300,000 living with severe alopecia areata. The oral pill by Eli Lilly, called Olumiant, works by blocking the immune system from attacking hair follicles, helping regrow hair. The American Academy of Dermatology Association notes on its website how a few cancer patients who received a drug called nivolumab to treat lung cancer and melanoma have also developed alopecia areata, but the link still remains unclear.
Her professional interests include Mohs micrographic surgery, cosmetic and laser procedures, and immunodermatology. Both Bordone and Strachan caution against seeking implant treatments for alopecia, even though it can be tempting. Dermatologists analyze factors like medical history, type of baldness (such as male pattern baldness), or underlying conditions like autoimmunity to recommend appropriate options approved by the U.S. Specifically, the treatment is a Janus kinase (JAK) inhibitor, which blocks the activity of a specific family of enzymes, interfering with the pathway that leads to inflammation, according to the agency. Jocelyn Solis-Moreira (she/her) is a science contributor at Popular Science. She covers a range of topics, including neuroscience, climate change, mental health, and infectious diseases.
Find a UCI Health Clinician that’s right for you.
Deuruxolitinib obtained FDA approval in July 2024, but its commercial debut remained on hold because of a patent-related injunction, although this has been very recently rendered vacant 13. All three of these medications carry the standard black-box warning required by the FDA for JAK inhibitors warning patients of potential severe adverse events, including serious infections, cardiovascular events, cancer, and death 14. On Monday, the Food and Drug Administration approved baricitinib, a once-a-day pill developed by the drugmaker Eli Lilly to treat alopecia areata, an autoimmune disease that triggers sudden hair loss. The drug was originally approved by the FDA in 2018 to treat rheumatoid arthritis. It wasn’t until 2022 that the FDA officially greenlighted one of these drugs—baricitinib, a.k.a. Olumiant—specifically for adults with alopecia.
